Nektar's Novel Opioid Unanimously Rejected by US FDA Advisory Cmte.
Executive Summary
But more data on abuse potential and efficacy could offer path for forward for oxycodegol even after the FDA product-specific advisory committee meeting for an opioid analgesic in more than a year goes very badly for the sponsor.